Class
Long R3 IGF-1 Analogue — Extended Half-life Growth Factor
Molecular Weight
9,111 Da (83 amino acids)
Half-life
20–30 hours (vs 15 min native IGF-1)
Purity
≥98% (HPLC)
Form
Lyophilized powder
Storage
Lyophilized: −20°C; Reconstituted in 0.1% acetic acid: 4°C
Reconstitution
0.1% acetic acid (acidified water)
Mechanism of action
IGF-1 LR3 is an 83-amino-acid analogue of human IGF-1 with an N-terminal 13-amino-acid extension and a Glu→Arg substitution at position 3. These modifications dramatically reduce binding to IGF binding proteins (IGFBPs), extending plasma half-life from ~15 minutes to 20–30 hours. IGF-1 signals through IGF-1R and secondarily IR to activate PI3K/AKT and MAPK/ERK pathways, driving protein synthesis, glucose uptake, cell proliferation, and anti-apoptotic signaling.
⚠️ For Research Use Only — described exclusively for in vitro and laboratory research by qualified researchers. Not for human or veterinary use. Informational only; does not constitute medical advice or imply efficacy in humans.
Research highlights
20–30h
Half-life (vs 15 min native IGF-1)
↓ IGFBP
Dramatically reduced binding protein affinity
↑ mTOR
Muscle protein synthesis pathway activation
PI3K/AKT
Dual signaling: anabolic + survival pathways
Research notes
- Myosatellite cells: Key research on muscle fiber repair, hypertrophy, and hyperplasia in in vitro and animal models.
- Protein synthesis: Consistent upregulation of mTOR pathway markers in skeletal muscle tissue research.
- Neuroprotection: IGF-1 receptor signaling extensively studied in neuronal survival and differentiation models.
- Bone: Positive effects on osteoblast activity and bone mineral density in animal models.
- IGFBP independence: The LR3 modification dramatically increases bioavailability vs unmodified IGF-1.
